Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Chief Dev & Operating Officer | April 16, 2026 | April 17, 2026 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Chief Dev. & Operating Officer | April 08, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date April 16, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-04-15 | Direct | 800,000 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 800,000 · Balance 800,000 F1: One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter.
Crinetics Pharmaceuticals, Inc.
Report date April 08, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,289 |
Ending reported balance
After 2026-04-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-04-08 · Exercise / conversion · Acquired 49,474 · Balance 161,492 Row 2 · 2026-04-08 · Exercise / conversion · Acquired 9,624 · Balance 171,116 Row 3 · 2026-04-08 · Exercise / conversion · Acquired 19,336 · Balance 190,452 Row 4 · 2026-04-08 · Sale · Disposed 85,163 · Balance 105,289 F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F2: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.98 · Expires 2031-09-01 | Direct | 63,027 |
Reported balance
After 2026-04-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-08 · Exercise / conversion · Disposed 49,474 · Balance 63,027 F3: 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2032-02-29 | Direct | 10,589 |
Reported balance
After 2026-04-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-08 · Exercise / conversion · Disposed 9,624 · Balance 10,589 F4: 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2033-03-01 | Direct | 65,977 |
Reported balance
After 2026-04-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-08 · Exercise / conversion · Disposed 19,336 · Balance 65,977 F5: The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
F2: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F3: 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments.
F4: 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022.
F5: The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 17, 2026 20:15 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001193125-26-161558 · ownership.xml · derivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Dev & Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2036-04-15 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,336 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · derivative · entry 7 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,977 Underlying: Common Stock · 19,336 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,624 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · derivative · entry 6 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,589 Underlying: Common Stock · 9,624 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,474 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · derivative · entry 5 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,027 Underlying: Common Stock · 49,474 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 85,163 | $40.10 | $3,415,036.30 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · nonDerivative · entry 4 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,289 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 19,336 | $19.64 | $379,759.04 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · nonDerivative · entry 3 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 9,624 | $20.02 | $192,672.48 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 49,474 | $23.98 | $1,186,386.52 |
DisclosureSEC source: 0001628280-26-024716 · wk-form4_1775853233.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Dev. & Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:13 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,961 | $37.77 | $149,606.97 |
DisclosureSEC source: 0001628280-26-019503 · wk-form4_1773868401.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,018 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:13 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 5,950 | $37.11 | $220,804.50 |
DisclosureSEC source: 0001628280-26-019503 · wk-form4_1773868401.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,979 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:34 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $43.79 | $0.00 |
DisclosureSEC source: 0001628280-26-011723 · wk-form4_1772055288.xml · derivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2036-02-23 F3 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:34 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011723 · wk-form4_1772055288.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,929 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027. F2 · balance_after: Includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 22:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 361 | $34.83 | $12,573.63 |
DisclosureSEC source: 0000950170-25-043404 · ownership.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,491 F3 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 22:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 6,801 | $34.17 | $232,390.17 |
DisclosureSEC source: 0000950170-25-043404 · ownership.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,852 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $36.86 | $0.00 |
DisclosureSEC source: 0000950170-25-025666 · ownership.xml · derivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 43,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-025666 · ownership.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,653 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 501 | $56.52 | $28,316.52 |
DisclosureSEC source: 0000950170-24-131064 · ownership.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,653 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 501 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 5,687 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · derivative · entry 7 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,313 Underlying: Common Stock · 5,687 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 2,887 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · derivative · entry 6 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,213 Underlying: Common Stock · 2,887 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 17,499 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · derivative · entry 5 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,501 Underlying: Common Stock · 17,499 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 27,000 | $55.00 | $1,485,000.00 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · nonDerivative · entry 4 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,653 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 5,687 | $19.64 | $111,692.68 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · nonDerivative · entry 3 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 2,887 | $20.02 | $57,797.74 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 17,499 | $23.98 | $419,626.02 |
DisclosureSEC source: 0000950170-24-084346 · ownership.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 21:31 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 956 | $44.38 | $42,427.28 |
DisclosureSEC source: 0000950170-24-079152 · ownership.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,580 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 956 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001209191-24-005081 · doc4.xml · derivative · entry 4 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 30,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 2,359 | $45.39 | $107,075.01 |
DisclosureSEC source: 0001209191-24-005081 · doc4.xml · nonDerivative · entry 3 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,580 Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 30,000 | $44.22 | $1,326,600.00 |
DisclosureSEC source: 0001209191-24-005081 · doc4.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,939 F1 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.22 per share. The range of sales prices on the transaction date was $44.00 to $44.52 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 30,000 | $23.98 | $719,400.00 |
DisclosureSEC source: 0001209191-24-005081 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 22:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 4,283 | $38.14 | $163,353.62 |
DisclosureSEC source: 0001209191-24-005012 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,939 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022 and March 1, 2023. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:59 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $43.51 | $0.00 |
DisclosureSEC source: 0001209191-24-004606 · doc4.xml · derivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2034-03-03 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:59 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004606 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,222 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025. Read SEC document |
| November 20, 2023 Filed Feb 12, 2024 21:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 931 | $14.98 | $13,946.38 |
DisclosureSEC source: 0001209191-24-003095 · doc5.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,222 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| May 22, 2023 Filed Feb 12, 2024 21:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 891 | $14.98 | $13,347.18 |
DisclosureSEC source: 0001209191-24-003095 · doc5.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,291 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 21:08 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 587 | $17.12 | $10,049.44 |
DisclosureSEC source: 0001209191-23-019768 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 91,000 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001209191-23-015556 · doc4.xml · derivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2033-02-28 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 29,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015556 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,987 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document |
| November 20, 2022 Filed Jan 27, 2023 21:27 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 537 | $15.16 | $8,140.92 |
DisclosureSEC source: 0001209191-23-005253 · doc5.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,487 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| July 26, 2022 Filed Jul 29, 2022 20:26 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 1,152 | $20.70 | $23,846.86 |
DisclosureSEC source: 0001209191-22-043524 · doc4.xml · nonDerivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.7004 per share. The range of actual sales prices on the transaction date was $20.69 to $20.7016 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document |
| May 20, 2022 Filed Jul 29, 2022 20:26 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,152 | $17.44 | $20,090.88 |
DisclosureSEC source: 0001209191-22-043524 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,102 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 23,100 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001209191-22-015133 · doc4.xml · derivative · entry 2 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,100 Underlying: Common Stock · 23,100 shares Expires 2032-02-27 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 4,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015133 · doc4.xml · nonDerivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001209191-21-054490 · doc4.xml · derivative · entry 1 Knight Jeff E. · CIK 0001881007 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-08-30 F1 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.